Matching articles for "immunotherapy"
Issue 1749 · March 2, 2026
Drugs for Atopic Dermatitis

Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and…

Med Lett Drugs Ther. 2026 Mar 2; 68(1749):33-40 doi:10.58347/tml.2026.1749a
Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into or first appearing in adulthood or even old age. Guidelines for the treatment of AD have recently been updated.
Issue 1725 · March 31, 2025 Free
Treatment of Allergic Rhinitis and Allergic Conjunctivitis

Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2025 Mar 31; 67(1725):49-56 doi:10.58347/tml.2025.1725a
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1716 · November 25, 2024
Drugs for Asthma

The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.

Med Lett Drugs Ther. 2024 Nov 25; 66(1716):185-92 doi:10.58347/tml.2024.1716a
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.
Issue 1699 · April 1, 2024
Omalizumab (Xolair) for Food Allergy

Omalizumab ( Xolair – Genentech), a recombinant anti-IgE monoclonal antibody FDA-approved for treatment of allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, has now also been…

Med Lett Drugs Ther. 2024 Apr 1; 66(1699):54-6 doi:10.58347/tml.2024.1699b
Omalizumab ( Xolair – Genentech), a recombinant anti-IgE monoclonal antibody FDA-approved for treatment of allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, has now also been approved for use in conjunction with food allergen avoidance to reduce IgE-mediated food allergic reactions caused by accidental exposure in patients ≥1 year old. Omalizumab is the first drug to be approved in the US to reduce allergic reactions to more than one food. Palforzia , an oral peanut allergen powder, was approved in 2020 to mitigate allergic reactions caused by accidental peanut exposure in patients with a confirmed peanut allergy.
Issue 1675 · May 1, 2023
Cyclosporine Ophthalmic Emulsion (Verkazia) for Vernal Keratoconjunctivitis

The FDA has approved Verkazia (Santen), a 0.1% ophthalmic emulsion formulation of the calcineurin inhibitor cyclosporine, for treatment of vernal keratoconjunctivitis (VKC). Verkazia is the first product to be…

Med Lett Drugs Ther. 2023 May 1; 65(1675):70-2 doi:10.58347/tml.2023.1675d
The FDA has approved Verkazia (Santen), a 0.1% ophthalmic emulsion formulation of the calcineurin inhibitor cyclosporine, for treatment of vernal keratoconjunctivitis (VKC). Verkazia is the first product to be approved in the US for this indication.
Issue 1622 · April 19, 2021
Drugs for Allergic Rhinitis and Allergic Conjunctivitis

The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):57-64
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1613 · December 14, 2020
Drugs for Asthma

The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations of asthma in the emergency department is not discussed here.

Med Lett Drugs Ther. 2020 Dec 14; 62(1613):193-200
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations of asthma in the emergency department is not discussed here.
Issue 1600 · June 15, 2020
Drugs for Atopic Dermatitis

Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and…

Med Lett Drugs Ther. 2020 Jun 15; 62(1600):89-96
Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into (or first appearing in) adulthood or even old age.
Issue 1593 · March 9, 2020
Peanut Allergen Powder (Palforzia)

The FDA has approved peanut allergen powder-dnfp ( Palforzia – Aimmune) for use as oral immunotherapy to mitigate allergic reactions, including anaphylaxis, caused by accidental peanut exposure in patients…

Med Lett Drugs Ther. 2020 Mar 9; 62(1593):33-4
The FDA has approved peanut allergen powder-dnfp ( Palforzia – Aimmune) for use as oral immunotherapy to mitigate allergic reactions, including anaphylaxis, caused by accidental peanut exposure in patients with a confirmed peanut allergy. It is the first drug to be approved in the US for this indication; Viaskin Peanut, an immunotherapy patch, is under FDA review for the same indication.
Issue 1541 · February 26, 2018
Odactra - Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis

The FDA has approved Odactra (ALK), a sublingual allergen extract, for immunotherapy in adults 18-65 years old with house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis. Odactra is…

Med Lett Drugs Ther. 2018 Feb 26; 60(1541):37-9
The FDA has approved Odactra (ALK), a sublingual allergen extract, for immunotherapy in adults 18-65 years old with house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis. Odactra is the first sublingual allergen extract to be approved in the US for this indication. Three other sublingual allergen extracts were approved earlier (see Table 1).
Issue 1528 · August 28, 2017
Drugs for Asthma

The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of acute exacerbations of asthma is not discussed here.

Med Lett Drugs Ther. 2017 Aug 28; 59(1528):139-46
The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of acute exacerbations of asthma is not discussed here.
Issue 1520 · May 8, 2017
Drugs for Allergic Disorders

Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation…

Med Lett Drugs Ther. 2017 May 8; 59(1520):71-82
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation H 1 -antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
Issue 114 · February 1, 2012
Drugs for Asthma

Inhalation is the preferred route of delivery for most asthma drugs. Chlorofluorocarbons (CFCs), which have ozone-depleting properties, are being phased out as propellants in metered-dose inhalers.…

Treat Guidel Med Lett. 2012 Feb; 10(114):11-8
Inhalation is the preferred route of delivery for most asthma drugs. Chlorofluorocarbons (CFCs), which have ozone-depleting properties, are being phased out as propellants in metered-dose inhalers. Non-chlorinated hydrofluoroalkane (HFA) propellants, which do not deplete the ozone layer, are being used instead.
Issue 76 · December 1, 2008
Drugs for Asthma

No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become…

Treat Guidel Med Lett. 2008 Dec; 6(76):83-90
No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become available.
Issue 33 · May 1, 2005
Drugs for Asthma

Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other…

Treat Guidel Med Lett. 2005 May; 3(33):33-8
Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other than for exercise-induced bronchospasm, indicates a need for anti-inflammatory treatment. Inhaled corticosteroids are the most effective anti-inflammatory medication; leukotriene modifiers are less effective alternatives. If regular use of an inhaled corticosteroid in a low dose does not prevent symptoms, a long-acting beta2-agonist should be added; addition of a second drug is more effective than raising the dose of the inhaled steroid. A leukotriene modifier can also be used as the second drug. Omalizumab may be considered as adjunctive therapy for patients more than 12 years old who have allergic asthma not controlled by other drugs. A short course of oral corticosteroids may be useful for acute exacerbations. Treatment of acute severe asthma as a medical emergency is not included here; it has been reviewed elsewhere (ER McFadden Jr, Am J Respir Crit Care Med 2003; 168:740) .